Cargando…
Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment
Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use is associated with increased immune-related adverse events. We re...
Autores principales: | León Mengíbar, Jose, Capel, Ismael, Bonfill, Teresa, Mazarico, Isabel, Casamitjana Espuña, Laia, Caixàs, Assumpta, Rigla, Mercedes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115434/ https://www.ncbi.nlm.nih.gov/pubmed/31310083 http://dx.doi.org/10.1530/EDM-19-0045 |
Ejemplares similares
-
Takotsubo cardiomyopathy in amiodarone-induced hyperthyroidism
por: Capel, Ismael, et al.
Publicado: (2017) -
Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
por: Patel, Shivani, et al.
Publicado: (2019) -
Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014) -
New onset autoimmune diabetes mellitus and hypothyroidism secondary to pembrolizumab in a patient with metastatic lung cancer
por: Cunha, Clara, et al.
Publicado: (2022) -
New-onset insulin-dependent diabetes due to nivolumab
por: Zaied, Ali A, et al.
Publicado: (2018)